News

William Towner, MD, FACP, FIDSA, is the regional physician director for the Division of Clinical Trials and leads the Clinician Investigator Program for the Southern California Permanente Medical Group. He also serves in a leadership role for HIV services at Kaiser Permanente Southern California. He was extensively involved in research on infectious diseases since 2000 ...

Research released in The Lancet Respiratory Medicine shows that a booster dose of the Pfizer COVID-19 vaccine provides strong protection, roughly 80% in the first few months against hospital admissions and emergency department visits caused by the delta and omicron variants. However, against omicron, this protection wanes over time for immunocompromised individuals — even after ...

A Kaiser Permanente study conducted in Southern and Northern California found hospitalizations for heart attack, stroke, and heart failure were 17% higher in the 5 days after the 2020 election than in the same 5 days 2 weeks before the election. The study was published April 20, 2022, in JAMA Network Open. “This study of the ...

Cheng-Wei “Charlie” Huang, MD, is a hospitalist at the Kaiser Permanente Los Angeles Medical Center who has spent recent years also focused on research that can improve care for patients. In addition to his research and clinical duties, Dr. Huang is the assistant program director of the  Los Angeles Medical Center’s internal medicine residency, where ...

Shoulder pain and injury are extremely rare after any type of vaccination in the upper arm, according to pre-pandemic Kaiser Permanente research published March 22, 2022, in Annals of Internal Medicine. Conducted from April 2016 through December 2017, the study found fewer than 1 in 10,000 people reported shoulder injuries in the more than 2.2 million ...

Kaiser Permanente research published Feb. 21, 2022, in Nature Medicine shows that while Moderna COVID-19 vaccine protection is strong against coronavirus infection by the delta variant, it is not as strong against infection from the omicron variant. Three doses of the Moderna COVID-19 vaccine were highly effective against hospitalization caused by infection from either the omicron ...

Kaiser Permanente Southern California is participating in a clinical trial of a novel vaccine against invasive E. coli infections in older adults. William Towner, MD, the principal investigator for Kaiser Permanente Southern California, said, “I’m enthusiastic about this cutting-edge research because it has the potential, if successful, to reduce morbidity and mortality from a very common ...

A Kaiser Permanente study published February 14, 2022, in The Lancet Regional Health – Americas found that 1 month after a third dose, the Pfizer-BioNTech COVID-19 vaccine effectiveness is higher for preventing infection and hospitalization than 2 doses of the vaccine after 1 month. “When we looked at the effectiveness of the 2 doses of Pfizer–BioNTech ...